You are in: eMedicine Specialties > Pediatrics: General Medicine > Gastroenterology Sandifer SyndromeArticle Last Updated: May 22, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Pegeen Eslami, MD, Assistant Professor of Pediatrics, Division of Pediatric Emergency Medicine, UMass Memorial Medical Center Pegeen Eslami is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, American College of Emergency Physicians, and Massachusetts Medical Society Coauthor(s): Raj D Sheth, MD, Professor, Departments of Neurology and Pediatrics, Director of Comprehensive Epilepsy Program, Department of Neurology, University of Wisconsin at Madison Editors: Jorge H Vargas, MD, Clinical Professor of Pediatrics, Division of Pediatric Gastroenterology, Hepatology & Nutrition; Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine.com, Inc; David A Piccoli, MD, Chief, Division of Gastroenterology and Nutrition, Department of Pediatrics, The Children's Hospital of Philadelphia; Professor, University of Pennsylvania School of Medicine; Steven M Schwarz, MD, FAAP, FACN, AGAF, Professor of Pediatrics, State University of New York, Downstate Medical Center College of Medicine; Distinguished Lecturer, New York Medical College, School of Public Health; Carmen Cuffari, MD, Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine Author and Editor Disclosure Synonyms and related keywords: Sandifer syndrome, Sandifer's syndrome, gastroesophageal reflux, gastroesophageal reflux disease, GERD, hiatal hernia, Sandifer's complex, Sandifer complex, torsional spasms, spasmodic torsional dystonia, esophagitis, torticollis, cerebral palsy, esophageal dysmotility INTRODUCTIONBackgroundSandifer syndrome involves spasmodic torsional dystonia with arching of the back and rigid opisthotonic posturing, mainly involving the neck, back, and upper extremities, associated with either gastroesophageal reflux or the presence of hiatal hernia.1 PathophysiologyThe true pathophysiologic mechanisms of this condition remain unclear. FrequencyInternationalThe incidence is unknown, although some suggestion indicates that in clinical practice it occurs in less than 1% of children with gastroesophageal reflux. Mortality/MorbidityMortality is not typically associated with Sandifer syndrome. RaceRace does not seem to influence incidence. SexNo sex predilection is recognized. AgeTypically, Sandifer syndrome is observed from infancy to early childhood. Peak prevalence is in individuals aged 18-36 months. Children with severe mental impairment or spasticity may experience Sandifer syndrome into adolescence. CLINICALHistorySandifer syndrome is most commonly mistaken for seizures. The child typically appears to have an alteration in mental status associated with the tonic posturing.
PhysicalIn children with Sandifer syndrome without mental impairment, the examination findings are normal. Children with Sandifer syndrome with mental impairment often have evidence of spasticity and may be diagnosed with cerebral palsy.5
CausesDysfunction of the lower esophagus is thought to be the most common precipitating factor. In some children, a cause cannot be found.
DIFFERENTIALSGastroesophageal Reflux
|
| Drug Name | Metoclopramide (Reglan) |
|---|---|
| Description | Dopaminergic antagonist that works by increasing LES tone and gastric emptying. Stimulates muscular activity, leading to decrease in reflux. |
| Adult Dose | 10-15 mg PO qid |
| Pediatric Dose | 0.4-0.8 mg/kg/d PO/IV/IM divided qid; not to exceed to 5 mg/dose |
| Contraindications | Documented hypersensitivity; pheochromocytoma; GI hemorrhage, obstruction, or perforation; history of seizure disorders |
| Interactions | Anticholinergic agents may antagonize effects of metoclopramide; opiate analgesics may increase metoclopramide toxicity in CNS; metoclopramide may increase cyclosporine levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in history of mental illness and Parkinson disease; adverse effects include restlessness and dystonia (can treat with diphenhydramine); narrow therapeutic index (avoid overdosing) |
These agents are used as diagnostic tool in providing symptomatic relief in infants. Associated benefits include symptomatic alleviation of constipation (aluminium antacids) or loose stools (magnesium antacids).
| Drug Name | Aluminum hydroxide (ALternaGEL, Amphojel) |
|---|---|
| Description | Increases gastric pH above 4 and inhibits proteolytic activity of pepsin, reducing acid indigestion. Antacids can initially be used in mild cases. No effect on frequency of reflux but decreases its acidity. |
| Adult Dose | 5-15 mL/dose PO qd-qid |
| Pediatric Dose | 2.5-5 mL/dose PO qd-qid |
| Contraindications | Documented hypersensitivity |
| Interactions | Decreases effects of tetracyclines, ranitidine, ketoconazole, benzodiazepines, penicillamine, phenothiazines, digoxin, indomethacin, and isoniazid; corticosteroids decrease effects of aluminum in hyperphosphatemia |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in recent massive upper GI hemorrhage and in infants; renal failure may cause aluminum toxicity; can cause constipation |
| Drug Name | Magnesium hydroxide (Phillips Milk of Magnesia) |
|---|---|
| Description | Causes osmotic retention of fluid, which distends colon and increases peristaltic activity. Forms magnesium chloride in vivo after reacting with stomach hydrochloric acid. |
| Adult Dose | 1 mL/kg/dose PO qid ac and hs |
| Pediatric Dose | 2.5-5 mL as needed; not to exceed 20 mL/d |
| Contraindications | Documented hypersensitivity; colostomy; ileostomy; renal failure; fecal impaction; appendicitis |
| Interactions | Decreases effects of tetracyclines, digoxin, indomethacin, and iron salts |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in severe renal impairment and in infants; can cause diarrhea |
Like antacids, these agents do not reduce the frequency of reflux, but they decrease the amount of acid in the refluxate by inhibiting acid production. All are equipotent when used in equivalent doses. Work best in patients with nonerosive esophagitis. Because of proton pump inhibitor (PPI) superiority, H2 blockers are reserved for use in patients unable to tolerate PPIs.
| Drug Name | Cimetidine (Tagamet) |
|---|---|
| Description | Inhibits histamine at H2 receptors of gastric parietal cells, resulting in reduced gastric acid secretion, gastric volume, and hydrogen ion concentrations. |
| Adult Dose | 10-15 mg/kg/dose PO qid ac and hs or 800 mg PO bid or 400 mg PO qid |
| Pediatric Dose | Neonates: 5-10 mg/kg/d PO/IV/IM divided q8-12h Infants: 10–20 mg/kg/d PO/IV/IM divided q6-12h Children: 20-40 mg/kg/d PO/IV/IM divided q6h; not to exceed 300 mg/dose |
| Contraindications | Documented hypersensitivity |
| Interactions | Can increase blood levels of theophylline, warfarin, tricyclic antidepressants, triamterene, phenytoin, quinidine, propranolol, metronidazole, procainamide, and lidocaine |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | May increase levels of many drugs; adjust dose or discontinue treatment if changes in renal function occur; adverse effects include headache and pancytopenia |
| Drug Name | Ranitidine (Zantac) |
|---|---|
| Description | Inhibits histamine stimulation of the H2 receptor in gastric parietal cells, which reduces gastric acid secretion, gastric volume, and hydrogen ion concentrations. |
| Adult Dose | 3.5 mg/kg/dose PO bid/tid ac and hs or 75-150 mg PO bid |
| Pediatric Dose | Neonates and term infants: 2 mg/kg/d PO divided q12h or 1.5 mg/kg/d IV divided q12h Children: 4-5 mg/kg/d PO divided q8-12h; not to exceed 300 mg/d |
| Contraindications | Documented hypersensitivity |
| Interactions | May decrease effects of ketoconazole and itraconazole; may alter serum levels of ferrous sulfate, diazepam, nondepolarizing muscle relaxants, and oxaprozin |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in renal or liver impairment; if changes in renal function occur during therapy, consider adjusting dose or discontinuing treatment; adverse effects include headache and malaise |
| Drug Name | Famotidine (Pepcid) |
|---|---|
| Description | Competitively inhibits histamine at H2 receptor of gastric parietal cells, resulting in reduced gastric acid secretion, gastric volume, and hydrogen ion concentrations. |
| Adult Dose | 20 mg PO bid |
| Pediatric Dose | >1 year: 1 mg/kg/d PO/IV divided q12h; not to exceed 80 mg/d |
| Contraindications | Documented hypersensitivity |
| Interactions | May decrease effects of ketoconazole and itraconazole |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Adjust dose in renal insufficiency |
These agents are indicated in patients who need complete acid suppression (eg, infants with chronic respiratory disease or neurologic disabilities). Administer with the first meal of the day (children with nasogastric or gastrostomy tubes may have granules mixed with an acidic juice, then flush tubes to prevent blockage).
| Drug Name | Omeprazole (Prilosec) |
|---|---|
| Description | Decreases gastric acid secretion by inhibiting the parietal cell H+/K+-ATP pump. Used for the short-term treatment (4-8 wk) of GERD. |
| Adult Dose | 20-40 mg PO qd |
| Pediatric Dose | 0.7-3.3 mg/kg/d PO <30 kilograms: 20 mg/d PO initial >30 kilograms: 40 mg/d PO initial |
| Contraindications | Documented hypersensitivity |
| Interactions | May decrease effects of itraconazole and ketoconazole; may increase toxicity of warfarin, digoxin, and phenytoin |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Adverse effects include headache, rash, diarrhea, hypergastrinemia, and polyps |
Article Last Updated: May 22, 2008